Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
José Trigo(Instituto de Investigación Biomédica de Málaga), Vivek Subbiah(The University of Texas MD Anderson Cancer Center), Benjamin Besse(Université Paris-Sud), Víctor Moreno(Hospital Universitario Fundación Jiménez Díaz), Rafael López‐López(Complejo Hospitalario Universitario de Santiago), María Ángeles Sala(Hospital de Basurto), Solange Peters(University Hospital of Lausanne), Santiago Ponce(Universidad Complutense de Madrid), Cristian Fernández(PharmaMar (Spain)), Vicente Alfaro(PharmaMar (Spain)), Javier Gómez(PharmaMar (Spain)), Carmen Kahatt(PharmaMar (Spain)), Ali Zeaiter(PharmaMar (Spain)), Khalil Zaman(University Hospital of Lausanne), Valentina Boni(Hospital Universitario HM Sanchinarro), Jennifer Arrondeau(Hôpital Cochin), Maite Martínez(Complejo Hospitalario de Navarra), Jean‐Pierre Delord(Institut Claudius Regaud), Ahmad Awada(Institut Jules Bordet), Rebecca Kristeleit(University College London), M.E. Olmedo(Hospital Universitario Ramón y Cajal), Luciano Wannesson(Ospedale San Giovanni Bellinzona), Javier Valdivia(Hospital Universitario Virgen de las Nieves), María Jesús Rubio(Hospital Universitario Reina Sofía), Antonio Antón(Hospital Universitario Miguel Servet), John Sarantopoulos(The University of Texas MD Anderson Cancer Center), Sant P. Chawla(Sarcoma Oncology Center), Joaquín Mosquera(Complexo Hospitalario Universitario A Coruña), M. D’Arcangelo(Ospedale "Santa Maria delle Croci" di Ravenna), Armando Santoro(Istituti di Ricovero e Cura a Carattere Scientifico), Víctor M. Villalobos(University of Colorado Denver), Jacob Sands(Dana-Farber Cancer Institute), Luis Paz‐Ares(Hospital Universitario 12 De Octubre)
Cited by 454
Abstract
Related Papers
No related papers found
Powered by citation graph analysis